Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. - Wikidata - awgldk - TriplyDB

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.

http://www.wikidata.org/entity/Q37117735

about

From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia Therapy-related acute promyelocytic leukemia The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies How animal models of leukaemias have already benefited patients Targeting of leukemia-initiating cells in acute promyelocytic leukemia The clinical activity of arsenic trioxide, ascorbic acid, ifosfamide and prednisone combination therapy in patients with relapsed and refractory multiple myeloma miRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines.Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.Curing all patients with acute promyelocytic leukemia: are we there yet?Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy.Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia The effects of arsenic trioxide on DNA synthesis and genotoxicity in human colon cancer cells Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells.ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.Arsenic trioxide - An old drug rediscovered.Thioredoxin-1 inhibitor PX-12 induces human acute myeloid leukemia cell apoptosis and enhances the sensitivity of cells to arsenic trioxide Differentiation of NUT midline carcinoma by epigenomic reprogramming.Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.Pathways of arsenic uptake and efflux.A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710.Advances in treating acute myeloid leukemia.Catechins induced acute promyelocytic leukemia cell apoptosis and triggered PML-RARα oncoprotein degradation.As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.Molecular diagnostics in acute leukemias.Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomas Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.Phase 1 study of arsenic trioxide, high-dose cytarabine, and idarubicin to down-regulate constitutive signal transducer and activator of transcription 3 activity in patients aged <60 years with acute myeloid leukemia Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide Treatment of acute promyelocytic leukemia with single-agent arsenic trioxide.Newly diagnosed acute promyelocytic leukemia History of acute promyelocytic leukemia: a tale of endless revolution Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.Future perspectives of Chinese medical formulae: chinmedomics as an effector.

P2860

Q24605527-4B437EF3-97EB-4656-9E28-9030337B02BF Q24629042-2515AC8A-09D4-43CE-8916-F1CDF06E9A56 Q26853348-61DB47BF-AEA2-41CD-A035-BD555F2EA114 Q26997702-0B6C18FC-E945-4497-9239-A339E7B5BB81 Q28083807-254E8F5D-415E-4960-BA17-5F06B244D889 Q33422349-7ED4177C-4232-465A-A394-6BEFFEE2ACF0 Q33530333-1636D246-F6FB-448A-A2AF-91EAC5804AAB Q33551142-5A95976E-F4DC-4B17-A4A1-A9757944811E Q33613426-AD6BFA81-0E9F-40B5-AEE5-F35CF1920ADB Q33631350-38AE0310-A63D-497C-AACB-34509A326D2D Q33710730-EAB534E0-176D-4CA6-A8B9-865ACD9E8731 Q33965775-1AA28B29-0746-416C-8EF1-E45573639231 Q33977987-626E70B3-80F5-4AB2-8A97-0388C9BBA3F2 Q34046794-50FEA3C5-A238-433B-8905-2C08B427F7DD Q34054167-2F100EF5-71DC-49CE-A56B-D994CD772058 Q34121354-58DD03DE-D464-4E82-B546-CE56CA35EFCD Q34174143-3D4553B6-107C-4117-8AC5-3138375AAB29 Q34267886-0E8651E4-5B7C-4DEF-B645-21907B7CF439 Q34304715-60743081-8456-421D-B398-61EA0EECF299 Q34305899-E4430D52-AC75-4349-B72A-9FA2D7AD74C3 Q34310859-D34D295B-2A4C-4F89-BC67-8A2B6DC87E1B Q34312351-AA77D303-6F67-4AE8-A984-A6EEB63A5F32 Q34339982-99E7EAF4-51F5-43D6-8671-785A0516FB93 Q34411016-C7EE54B4-A9B2-4015-9618-4D75AADFDD38 Q34420787-4928EC44-2C39-4A2A-86B2-60DEDA325D50 Q34571624-F3F72123-D113-4EAB-B6D6-A221CD96B315 Q34658892-421C9070-9F5E-418A-9898-FBDC0BCD79F6 Q34754867-830078AC-E04F-4A5D-9310-816C91732DAE Q35007333-C159D452-AEA3-4BEB-BD07-7AFEFE3CAAB1 Q35046691-2314F703-1C8F-43FC-96D3-C2BBDDEE00A4 Q35058617-61DD4559-3709-4A19-880B-2B9F78E7C1DD Q35085867-DFB28E14-6377-4DB0-951E-12535F5B68F2 Q35563628-2C4EF779-7BE3-41D9-9D49-4E169C5469DD Q35640744-77DF0D9E-6E6A-4B13-BFCF-35C06536C114 Q35640773-E8D90D28-D1E6-4087-8AE7-287CE0213278 Q35640780-18E1CADA-C6DD-4A7B-9608-C3BF774DB2EB Q35904994-747DB025-2001-49D2-BDDB-A003646C677B Q35949253-A515BD5D-54FA-4073-BFD6-5346680F686B Q36070904-01B606D6-3782-4C1D-BFD0-597260E86E5E Q36089546-57D991AA-2B59-4312-B52F-715CC7D06CA3

P2860

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia.

http://www.wikidata.org/entity/Q37117735

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Long-term efficacy and safety ...... acute promyelocytic leukemia.

@en

Long-term efficacy and safety ...... acute promyelocytic leukemia.

@nl

type

label

Long-term efficacy and safety ...... acute promyelocytic leukemia.

@en

Long-term efficacy and safety ...... acute promyelocytic leukemia.

@nl

prefLabel

Long-term efficacy and safety ...... acute promyelocytic leukemia.

@en

Long-term efficacy and safety ...... acute promyelocytic leukemia.

@nl

P1433

Q37117735-2C83F94D-8564-45E8-9512-A54C264F7AAC

P1476

Q37117735-8DD1C3A0-C0E0-4CDD-91CB-19B3B156DC7A

P2093

Q37117735-0619878B-5350-4A2D-835C-18761E5456EB

Q37117735-3F7D5D8B-9F8B-4D3C-95AE-33F84EF806D9

Q37117735-67C19573-347A-4623-AED0-D65C54C6AC97

Q37117735-721D4A12-D509-4BA1-B5D9-0CEAD2917F9C

Q37117735-7537DD4E-640E-4FA6-B66B-42078A51E166

Q37117735-7A850347-5C77-4B1E-83D3-D56871DA1774

Q37117735-812C0018-6185-4008-88C5-840481EF6E93

Q37117735-9B0FCF4D-AD26-42FB-8FEE-D6D9C8F3FE50

Q37117735-A2D3F0C7-837A-411E-BA0C-D230E93EB62D

Q37117735-A46D993A-14F9-445D-A011-677EDBB10235

P2860

Q37117735-030F9957-4DF7-4357-86AB-193AC0C54A00

Q37117735-299EEB1F-DC45-426F-B676-5F9D7072A4AA

Q37117735-2E960168-DEC2-4830-B2D1-0AB9C94BC25C

Q37117735-2E9A06BA-0493-4D3A-84B0-E778AAFD0566

Q37117735-2F77E4BF-929E-4D47-B86C-4D6448A852DF

Q37117735-308C0FCD-362D-4627-96D0-6D021DABDF7B

Q37117735-41B1C22C-5BA2-47D4-9BC8-0AF0068230C2

Q37117735-4662E43B-9D9F-49AB-A685-F2989CFC74BE

Q37117735-47780A09-9442-4B78-BDFC-8EC3E726A0D2

Q37117735-4DF7D9F0-554A-4360-831B-5BAC38E30368

P304

Q37117735-66718256-CC8C-48A0-88CE-4E4AD5FFBCFC

P31

Q37117735-29EEEC8E-8075-4F16-B39A-94444516DEA7

P356

Q37117735-6EA009A6-C8DA-4407-99FF-AEEC27F2B51C

P407

Q37117735-D6C210D7-CDD5-465C-828A-B73C33D701F8

P433

Q37117735-FF6EAE57-AB36-412B-8891-F88606F3FF64

P478

Q37117735-B468E623-F1AE-4DE2-8E7D-10EC63213BB2

P50

Q37117735-0F1CF6C8-6333-48EB-97B2-AFC02F4883C8

Q37117735-F842EC11-7C8B-476A-A49D-67414E520B1A

P577

Q37117735-D36B3729-0689-4104-A03A-B78B8DAE4429

P5875

Q37117735-711596B9-24B9-4684-89E1-1E81666925B2

P698

Q37117735-2A44AEA1-9C91-415B-80C2-98E72AE3B336

P921

Q37117735-B951017E-6EBB-4A19-AD07-DCEEE6CBCACD

P932

Q37117735-687D1AB9-DA5E-4791-8C75-F03735D83D6B

P356

PNAS.0813280106

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Long-term efficacy and safety ...... acute promyelocytic leukemia.

@en

P2093

Arthur Zelent

http://www.w3.org/2001/XMLSchema#string

Bing Chen

http://www.w3.org/2001/XMLSchema#string

Chuan-Feng Wu

http://www.w3.org/2001/XMLSchema#string

Fang Xu

http://www.w3.org/2001/XMLSchema#string

Hui-Ping Sun

http://www.w3.org/2001/XMLSchema#string

Jiong Hu

http://www.w3.org/2001/XMLSchema#string

Jun-Min Li

http://www.w3.org/2001/XMLSchema#string

Qiu-Sheng Chen

http://www.w3.org/2001/XMLSchema#string

Sai-Juan Chen

http://www.w3.org/2001/XMLSchema#string

Wei Tang

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients.

Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia

Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia

Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia

Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group.

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia.

Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia.

All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.

Acute promyelocytic leukemia.

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

P304

3342-3347

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0813280106

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24023105

http://www.w3.org/2001/XMLSchema#string

P698

19225113

http://www.w3.org/2001/XMLSchema#string

P921

P932

2651325

http://www.w3.org/2001/XMLSchema#string